Hallmarks of primary headache: part 3 - cluster headache.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Coppola Gianluca, Arruda Marco Antônio, Ashina Messoud, Barloese Mads, Belin Andrea Carmine, Bottiroli Sara, Chowdhury Debashish, De Icco Roberto, Di Lorenzo Cherubino, Di Stefano Giulia, Edvinsson Jacob C A, Evers Stefan, Ferraro Stefania, Fronczek Rolf, García-Azorín David, Goadsby Peter J, Grazzi Licia, Holle Dagny, Jansen Julia J, Gil-Gouveia Raquel, Lambru Giorgio, Lanteri-Minet Michel, Lisicki Marco, Mitsikostas Dimos D, Monteith Teshamae, Montisano Danilo Antonio, Obermann Mark, Pan Li-Ling Hope, Peng Kuan-Po, Peres Mario, Petrušić Igor, Cecchini Alberto Proietti, Vila-Pueyo Marta, Raggi Alberto, Rainero Innocenzo, Sandrini Giorgio, Sebastianelli Gabriele, Takizawa Tsubasa, Tanprawate Surat, Tassorelli Cristina, Truini Andrea, Valeriani Massimiliano, Vuralli Doga, Waliszewska-Prosół Marta, Wang Shuu-Jiun, Wang Yonggang, Wijeratne Tissa, Martelletti Paolo
Аннотация
PRINCIPAL FINDINGS: Despite its distinctive clinical and chronobiological features, CH may be mistaken for other primary headache disorders or different types of orofacial pain. Key pathogenic characteristics include the activation of the trigeminal-autonomic system with the release of several neuropeptides, the involvement of the hypothalamus in regulating the circadian rhythm, genetic variants, and the mesolimbic system. Both invasive and non-invasive neuromodulation treatments have been used to target the trigemino-cervical, parasympathetic, and hypothalamic systems. Additionally, novel therapeutic targets are currently being study. Alongside canonical therapies, several complementary approaches have been explored over the years, with most evidence deriving from uncontrolled research involving individuals who do not respond to standard pharmacological treatments. Despite advancements in our understanding of this complex disease, CH continues to pose considerable social, economic, and psychological challenges. Advocacy is essential and should prioritize early diagnosis, alleviate stigma, provide specialized training for healthcare professionals, and offer support to and through patient associations.
CONCLUSIONS: CH is characterised by a complex, multifactorial, pathophysiology that is still not fully understood. Precise diagnosis, additional research studies, and robust psychosocial and institutional support are necessary to improve the quality of life for individuals affected by this debilitating condition.